Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

University of Toronto

$70,000.00

Targeting Neuronal Calcium Sensor-1 to treat cognitive deficits in schizophrenia

FY 2012-13

Summary
Schizophrenia is a chronic mental disorder affecting 1% of people worldwide and cost Canadians an estimated $6.85 billion in 2004. Schizophrenia involves not only psychotic symptoms like hallucinations and delusions but also depressed mood, and impaired cognitive abilities like attention, learning and problem solving. Current drugs reduce the psychotic symptoms of schizophrenia, but they do not treat patient's cognitive deficits, making it difficult for patients with schizophrenia to make full functional recoveries and hold onto jobs. Cognitive deficits account for much of the long-term disability of schizophrenia and often appear before the psychotic phase of the disorder. Thus finding treatments for the cognitive deficits is crucial for the functional recovery of people with schizophrenia and may allow earlier treatments before the first psychotic episode. Cognitive abilities such as planning, abstract thinking and flexible switching of attention, are thought to depend on a brain area called the prefrontal cortex. Studies show that levels of the protein Neuronal Calcium Sensor-1 (NCS-1) are higher in the prefrontal cortex of people with schizophrenia, perhaps contributing to cognitive deficits. Therefore, I will test if there is a causal link between higher NCS-1 levels and schizophrenia and test if NCS-1 can be targeted to treat cognitive deficits. I hypothesize since schizophrenia is associated with increased NCS-1 in the prefrontal cortex, increasing NCS-1 in the analogous brain region in mice will cause them to exhibit behaviours relevant to schizophrenia and impaired cognition. Moreover, I expect decreasing NCS -1 will correct such behaviours or impaired cognition in these mice and other models of schizophrenia. Results from testing these hypotheses will pave the way to new treatment strategies for schizophrenia. Indeed, modeling cognitive deficits and finding novel ways to treat them is also relevant to other diseases with cognitive decline like Alzheimer's.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
283940
Name
Ng Enoch
Region
Ontario
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Targeting Neuronal Calcium Sensor-1 to treat cognitive deficits in schizophrenia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$70,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Behavioural Neuroscience; Biochemistry; Dopamine; Electrophysiology; Executive Function; Molecular Genetics; Neuronal Calcium Sensor-1; Neuropsychopharmacology; Schizophrenia; Viral-Mediated Gene Therapy
Abstract
Schizophrenia is a chronic mental disorder affecting 1% of people worldwide and cost Canadians an estimated $6.85 billion in 2004. Schizophrenia involves not only psychotic symptoms like hallucinations and delusions but also depressed mood, and impaired cognitive abilities like attention, learning and problem solving. Current drugs reduce the psychotic symptoms of schizophrenia, but they do not treat patient's cognitive deficits, making it difficult for patients with schizophrenia to make full functional recoveries and hold onto jobs. Cognitive deficits account for much of the long-term disability of schizophrenia and often appear before the psychotic phase of the disorder. Thus finding treatments for the cognitive deficits is crucial for the functional recovery of people with schizophrenia and may allow earlier treatments before the first psychotic episode. Cognitive abilities such as planning, abstract thinking and flexible switching of attention, are thought to depend on a brain area called the prefrontal cortex. Studies show that levels of the protein Neuronal Calcium Sensor-1 (NCS-1) are higher in the prefrontal cortex of people with schizophrenia, perhaps contributing to cognitive deficits. Therefore, I will test if there is a causal link between higher NCS-1 levels and schizophrenia and test if NCS-1 can be targeted to treat cognitive deficits. I hypothesize since schizophrenia is associated with increased NCS-1 in the prefrontal cortex, increasing NCS-1 in the analogous brain region in mice will cause them to exhibit behaviours relevant to schizophrenia and impaired cognition. Moreover, I expect decreasing NCS -1 will correct such behaviours or impaired cognition in these mice and other models of schizophrenia. Results from testing these hypotheses will pave the way to new treatment strategies for schizophrenia. Indeed, modeling cognitive deficits and finding novel ways to treat them is also relevant to other diseases with cognitive decline like Alzheimer's.
Competitiondate
201210
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Ng, Enoch
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $70,000~ $0~